{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:07:26Z","timestamp":1789031246960,"version":"build-2803163510"},"reference-count":78,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372855"],"award-info":[{"award-number":["82372855"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82503368"],"award-info":[{"award-number":["82503368"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"award":["82372855"],"award-info":[{"award-number":["82372855"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]},{"award":["82503368"],"award-info":[{"award-number":["82503368"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["22RZ1439200"],"award-info":[{"award-number":["22RZ1439200"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"award":["22RZ1439200"],"award-info":[{"award-number":["22RZ1439200"]}],"id":[{"id":"https:\/\/ror.org\/03kt66j61","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of Shanghai","doi-asserted-by":"publisher","award":["24RZ1446400"],"award-info":[{"award-number":["24RZ1446400"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Perioperative chemoimmunotherapy has become an important curative-intent strategy for selected patients with resectable non-small cell lung cancer (NSCLC). However, most pivotal trials evaluate neoadjuvant therapy, surgery, and postoperative immune checkpoint inhibitor (ICI) treatment as an integrated regimen. Whether continued postoperative immunotherapy provides independent incremental benefit for all patients after effective neoadjuvant chemoimmunotherapy and complete resection remains unresolved. This review focuses on the adjuvant-phase dilemma and discusses how postoperative treatment may be refined according to response and residual risk. Methods: We performed a narrative review of major neoadjuvant and perioperative chemoimmunotherapy trials, indirect comparative analyses, pathological-response studies, circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) evidence, immune biomarker studies, and emerging data in driver-positive and real-world populations. Particular attention was given to evidence informing postoperative continuation, de-escalation, or intensification after neoadjuvant chemoimmunotherapy. Results: Current phase III perioperative trials demonstrate clinically meaningful activity but do not isolate the independent contribution of the adjuvant ICI phase. Pathological response provides the most accessible postoperative risk signal: pathologic complete response identifies the deepest-response group, major pathologic response represents an intermediate state, and non-major pathologic response or persistent nodal disease suggests higher relapse risk. ctDNA-based MRD offers dynamic risk refinement and may help identify patients with residual systemic disease, although prospective validation is required before it can guide routine treatment omission or escalation. Programmed death-ligand 1 (PD-L1), tumor mutational burden, tertiary lymphoid structures, B-cell signatures, radiomics, and pathomics may provide complementary information but are not sufficient as standalone decision tools. Driver-positive disease requires molecularly stratified perioperative strategies rather than unselected extrapolation from epidermal growth factor receptor (EGFR)\/anaplastic lymphoma kinase (ALK)-negative trials. Conclusions: The key question in resectable NSCLC is shifting from whether perioperative immunotherapy is active to which patients truly require postoperative immunotherapy. Future trials should prospectively test response-guided strategies integrating pathological response, ctDNA-based MRD, immune contexture, baseline risk, and treatment feasibility.<\/jats:p>","DOI":"10.3390\/cancers18182933","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:07:41Z","timestamp":1789027661000},"page":"2933","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Adjuvant-Phase Dilemma After Neoadjuvant Chemoimmunotherapy in Resectable NSCLC: Evidence and Response-Guided Strategies"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3224-4686","authenticated-orcid":false,"given":"Jingyuan","family":"Fan","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichao","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runsen","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hecheng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1056\/NEJMra1703413","article-title":"Precision Diagnosis and Treatment for Advanced Non\u2013Small-Cell Lung Cancer","volume":"377","author":"Reck","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.37349\/etat.2024.00206","article-title":"Management of Stage III Non-Small-Cell Lung Cancer: Rays of Hope","volume":"5","author":"Kim","year":"2024","journal-title":"Explor. Target. Anti-Tumor Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.22.00825","article-title":"Therapy for Stage IV Non\u2013Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline","volume":"40","author":"Singh","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S1297","DOI":"10.1016\/j.annonc.2023.10.052","article-title":"LBA56 Overall Survival in the KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer (NSCLC)","volume":"34","author":"Spicer","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/CCO.0000000000001098","article-title":"Perioperative Immunotherapy in Nonsmall Cell Lung Cancer","volume":"37","author":"Zhang","year":"2025","journal-title":"Curr. Opin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"340","DOI":"10.6004\/jnccn.2023.0020","article-title":"NCCN Guidelines\u00ae Insights: Non\u2013Small Cell Lung Cancer, Version 2.2023: Featured Updates to the NCCN Guidelines","volume":"21","author":"Ettinger","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative Toripalimab Plus Chemotherapy for Patients with Resectable Non\u2013Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial","volume":"331","author":"Lu","year":"2024","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"LBA100","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA100","article-title":"KEYNOTE-671: Randomized, Double-Blind, Phase 3 Study of Pembrolizumab or Placebo plus Platinum-Based Chemotherapy Followed by Resection and Pembrolizumab or Placebo for Early Stage NSCLC","volume":"41","author":"Wakelee","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Bogatsa, E., Lazaridis, G., Stivanaki, C., and Timotheadou, E. (2024). Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC. Cancers, 16.","DOI":"10.3390\/cancers16091619"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S1607","DOI":"10.1016\/j.annonc.2025.09.079","article-title":"LBA67 Perioperative Pembrolizumab in Early-Stage Non-Small-Cell Lung Cancer (NSCLC): 5-Year Follow-up from KEYNOTE-671","volume":"36","author":"Wakelee","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa2502931","article-title":"Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer","volume":"393","author":"Forde","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Tao, Y., Li, X., Liu, B., Wang, J., Lv, C., Li, S., Wang, Y., Chen, J., Yan, S., and Wu, N. (2023). Association of Early Immune-Related Adverse Events with Treatment Efficacy of Neoadjuvant Toripalimab in Resectable Advanced Non-Small Cell Lung Cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1135140"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1200\/JCO.2024.42.16_suppl.8012","article-title":"Health-Related Quality of Life (HRQoL) Outcomes from the Randomized, Double-Blind Phase 3 KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer (NSCLC)","volume":"42","author":"Garassino","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab Compared with Neoadjuvant Chemotherapy Alone in Patients with Early-Stage Non-Small-Cell Lung Cancer (KEYNOTE-671): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/jnci\/djaf190","article-title":"Immune Checkpoint Inhibitors as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis","volume":"117","author":"Aburaki","year":"2025","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.21037\/tlcr-2025-426","article-title":"Efficacy and Safety of Perioperative, Adjuvant and Neoadjuvant Chemoimmunotherapy Stratified by Clinical Stage and PD-L1 Expression in Resectable Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis","volume":"14","author":"Wang","year":"2025","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Chen, K., Wang, X., Yue, R., Chen, W., Zhu, D., Cui, S., Zhang, X., Jin, Z., and Xiao, T. (2024). Efficacy and Safety of Immune Checkpoint Inhibitors as Neoadjuvant Therapy in Perioperative Patients with Non-Small Cell Lung Cancer: A Network Meta-Analysis and Systematic Review Based on Randomized Controlled Trials. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1432813"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e241285","DOI":"10.1001\/jamanetworkopen.2024.1285","article-title":"Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients with Resectable NSCLC: An Indirect Meta-Analysis","volume":"7","author":"Zhou","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative Durvalumab for Resectable Non\u2013Small-Cell Lung Cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative Nivolumab and Chemotherapy in Stage III Non\u2013Small-Cell Lung Cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.jtho.2024.09.022","article-title":"OA01.03 Association of Pathologic Regression with EFS in the KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC","volume":"19","author":"Jones","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"112078","DOI":"10.1016\/j.intimp.2024.112078","article-title":"Association of Pathological Response with Long-Term Survival Outcomes after Neoadjuvant Immunotherapy: A Meta-Analysis","volume":"133","author":"Wei","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jtho.2024.09.1443","article-title":"Improved Event-Free Survival After Complete or Major Pathologic Response in Patients with Resectable NSCLC Treated with Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis","volume":"20","author":"Marinelli","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e70195","DOI":"10.1111\/1759-7714.70195","article-title":"A Real-World Study of Resectable NSCLC Following Neoadjuvant Immunotherapy: Should Postoperative Adjuvant Immunotherapy Be Recommended?","volume":"16","author":"Li","year":"2025","journal-title":"Thorac. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"110148","DOI":"10.1016\/j.ejso.2025.110148","article-title":"Survival Outcome Comparison of Neoadjuvant and Perioperative ICI-Based Therapies in Patients with Non-Small Cell Lung Cancer Achieving MPR or pCR: A Systematic Review and Meta-Analysis","volume":"51","author":"Tao","year":"2025","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1093\/jnci\/djaf090","article-title":"Neoadjuvant vs Perioperative Chemo-Immunotherapy According to Pathological Response in Resectable Non-Small Cell Lung Cancer: A Reconstructed Individual Patient Data Meta-Analysis","volume":"117","author":"Nuccio","year":"2025","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s00262-025-04159-0","article-title":"Efficacy of Adjuvant Therapy Regimens Administered during the Perioperative Period in Resectable Non-Small Cell Lung Cancer","volume":"74","author":"Zhao","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"111339","DOI":"10.1016\/j.ejso.2025.111339","article-title":"Optimizing Adjuvant Therapy under the Guidance of MPR: A Multicenter Retrospective Analysis of Neoadjuvant Therapy in Non-Small Cell Lung Cancer","volume":"52","author":"Chen","year":"2026","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.7150\/jca.119881","article-title":"The Prognostic Value of Lymph Node Downstaging Following Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer","volume":"16","author":"Guo","year":"2025","journal-title":"J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.cllc.2025.04.004","article-title":"Prognostic Implications of Lymph Node Status in Non-Small-Cell Lung Cancer Patients Before and After Neoadjuvant Chemoimmunotherapy: A Multicenter Retrospective Study","volume":"26","author":"Ma","year":"2025","journal-title":"Clin. Lung Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jtcvs.2026.02.025","article-title":"Pathologic Response and Nodal Status Guide Adjuvant Immunotherapy in Non-Small Cell Lung Cancer after Neoadjuvant Chemoimmunotherapy: An Eastern Asian Cohort Study","volume":"172","author":"Pan","year":"2026","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.21037\/jtd-2024-2266","article-title":"Four-Year Outcomes with Perioperative Toripalimab plus Chemotherapy in Resectable Stage III Non-Small Cell Lung Cancer (NeoTAP01 Study)","volume":"17","author":"Zhou","year":"2025","journal-title":"J. Thorac. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"108635","DOI":"10.1016\/j.lungcan.2025.108635","article-title":"ETOP 25-23 ADOPT-Lung: An International, Multicentre, Open-Label Randomised Phase III Trial to Evaluate the Benefit of Adding Adjuvant Durvalumab after Neoadjuvant Chemotherapy plus Durvalumab in Patients with Stage IIB-IIIB (N2) Resectable NSCLC","volume":"206","author":"Schmid","year":"2025","journal-title":"Lung Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","article-title":"Personalized Response-Directed Surgery and Adjuvant Therapy after Neoadjuvant Ipilimumab and Nivolumab in High-Risk Stage III Melanoma: The PRADO Trial","volume":"28","author":"Reijers","year":"2022","journal-title":"Nat. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"8521","DOI":"10.1200\/JCO.2023.41.16_suppl.8521","article-title":"Clinical Outcomes with Neoadjuvant Nivolumab (N) + Chemotherapy (C) vs C by Definitive Surgery in Patients (Pts) with Resectable NSCLC: 3-y Results from the Phase 3 CheckMate 816 Trial","volume":"41","author":"Spicer","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.annonc.2024.01.005","article-title":"VP1-2024: RATIONALE-315: Event-Free Survival (EFS) and Overall Survival (OS) of Neoadjuvant Tislelizumab (TIS) plus Chemotherapy (CT) with Adjuvant TIS in Resectable Non-Small Cell Lung Cancer (NSCLC)","volume":"35","author":"Yue","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"(2021). Atezolizumab Extends DFS after NSCLC Relapse. Cancer Discov., 11, OF3.","DOI":"10.1158\/2159-8290.CD-NB2021-0384"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41571-023-00794-7","article-title":"Immune-Checkpoint Inhibition for Resectable Non-Small-Cell Lung Cancer\u2014Opportunities and Challenges","volume":"20","author":"Mountzios","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s44272-023-00010-8","article-title":"Perioperative Immunotherapy for Resectable Non-Small-Cell Lung Cancer","volume":"3","author":"Yang","year":"2024","journal-title":"Clin. Cancer Bull."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"112903","DOI":"10.1016\/j.intimp.2024.112903","article-title":"Advances in Clinical Trials on Perioperative Immune Checkpoint Inhibitors for Resectable Non-Small Cell Lung Cancer: A Comprehensive Review","volume":"141","author":"Cui","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Fukuda, S., Suda, K., Hamada, A., and Tsutani, Y. (2023). Recent Advances in Perioperative Immunotherapies in Lung Cancer. Biomolecules, 13.","DOI":"10.3390\/biom13091377"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 Blockade in Resectable Lung Cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Liu, X., Lv, W., Huang, D., and Cui, H. (2025). The Predictive Role of Tertiary Lymphoid Structures in the Prognosis and Response to Immunotherapy of Lung Cancer Patients: A Systematic Review and Meta-Analysis. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-13484-7"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1158\/1078-0432.CCR-25-3315","article-title":"Decoding B-Cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non\u2013Small Cell Lung Cancer","volume":"32","author":"Nadal","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Chen, H., Fan, B., Yuan, M., Wang, D., Qiao, C., Qiu, N., Quan, X., and Hou, W. (2026). CT-Based Radiomics in Predicting the Efficacy of Preoperative Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1753166"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s41747-024-00468-8","article-title":"CT and MRI Radiomic Features of Lung Cancer (NSCLC): Comparison and Software Consistency","volume":"8","author":"Bortolotto","year":"2024","journal-title":"Eur. Radiol. Exp."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"7058","DOI":"10.1158\/1078-0432.CCR-19-1213","article-title":"Perioperative Dynamic Changes in Circulating Tumor DNA in Patients with Lung Cancer (DYNAMIC)","volume":"25","author":"Chen","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.trecan.2024.04.004","article-title":"Implementing Circulating Tumor DNA as a Prognostic Biomarker in Resectable Non-Small Cell Lung Cancer","volume":"10","author":"Abbosh","year":"2024","journal-title":"Trends Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1158\/1078-0432.CCR-21-3044","article-title":"Perioperative ctDNA-Based Molecular Residual Disease Detection for Non\u2013Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1)","volume":"28","author":"Xia","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e2500977","DOI":"10.1200\/PO-25-00977","article-title":"Potential of Minimal Residual Disease in Guiding Adjuvant Therapy Decisions in Non\u2013Small Cell Lung Cancer","volume":"10","author":"Lei","year":"2026","journal-title":"JCO Precis. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1158\/2159-8290.CD-21-1486","article-title":"Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non\u2013Small Cell Lung Cancer","volume":"12","author":"Zhang","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.annonc.2022.02.007","article-title":"Residual ctDNA after Treatment Predicts Early Relapse in Patients with Early-Stage Non-Small Cell Lung Cancer","volume":"33","author":"Gale","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"105109","DOI":"10.1016\/j.ebiom.2024.105109","article-title":"Circulating Tumour DNA-Based Molecular Residual Disease Detection in Resectable Cancers: A Systematic Review and Meta-Analysis","volume":"103","author":"Zheng","year":"2024","journal-title":"EBioMedicine"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"103696","DOI":"10.1016\/j.jtho.2026.103696","article-title":"Consensus Statement on ctDNA Minimal Residual Disease Testing in Early Stage NSCLC: A Delphi Study by the Asian Thoracic Oncology Research Group","volume":"21","author":"Tan","year":"2026","journal-title":"J. Thorac. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41591-020-0915-3","article-title":"Genome-Wide Cell-Free DNA Mutational Integration Enables Ultra-Sensitive Cancer Monitoring","volume":"26","author":"Zviran","year":"2020","journal-title":"Nat. Med."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Angeles, A.K., Janke, F., Bauer, S., Christopoulos, P., Riediger, A.L., and S\u00fcltmann, H. (2021). Liquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in Cancer. Cancers, 13.","DOI":"10.3390\/cancers13225615"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"111805","DOI":"10.1016\/j.ejso.2026.111805","article-title":"Surgical Outcomes after Neoadjuvant Chemoimmunotherapy for Resectable NSCLC: A Systematic Review and Meta-Analysis","volume":"52","author":"Bertoglio","year":"2026","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"108760","DOI":"10.1016\/j.lungcan.2025.108760","article-title":"Attrition with Adjuvant, Neoadjuvant, and Perioperative Immunotherapy-Based Treatment Protocols in Patients with Resectable Non-Small-Cell Lung Cancer. A Meta-Analysis of Prospective Trials","volume":"209","author":"Guerrera","year":"2025","journal-title":"Lung Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jtho.2022.04.012","article-title":"Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC","volume":"17","author":"Zhang","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.athoracsur.2024.09.041","article-title":"The Society of Thoracic Surgeons Expert Consensus on the Multidisciplinary Management and Resectability of Locally Advanced Non-Small Cell Lung Cancer","volume":"119","author":"Kim","year":"2025","journal-title":"Ann. Thorac. Surg."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41392-023-01355-1","article-title":"Two vs Three Cycles of Neoadjuvant Sintilimab plus Chemotherapy for Resectable Non-Small-Cell Lung Cancer: neoSCORE Trial","volume":"8","author":"Shao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"12","DOI":"10.21037\/cco-23-137","article-title":"The Emerging Perioperative Treatment Paradigm for Non-Small Cell Lung Cancer: A Narrative Review","volume":"13","author":"Christopoulos","year":"2024","journal-title":"Chin. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.62347\/IFRH7248","article-title":"Adjuvant Osimertinib Therapy Guided by ctDNA-Assessed MRD in Resected EGFR-Mutated Stage IA-IIA Non-Small-Cell Lung Cancer: A Randomized Clinical Trial Study Protocol","volume":"14","author":"Wang","year":"2024","journal-title":"Am. J. Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"S731","DOI":"10.1016\/j.annonc.2023.09.739","article-title":"1261O Neoadjuvant Nivolumab (N) + Ipilimumab (I) vs. Chemotherapy (C) in the Phase III CheckMate 816 Trial","volume":"34","author":"Awad","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1158\/1078-0432.CCR-24-1441","article-title":"Facts and Hopes in Neoadjuvant Immunotherapy Combinations in Resectable Non\u2013Small Cell Lung Cancer","volume":"31","author":"Schuler","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"102106","DOI":"10.1016\/j.eclinm.2023.102106","article-title":"AK112, a Novel PD-1\/VEGF Bispecific Antibody, in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): An Open-Label, Multicenter, Phase II Trial","volume":"62","author":"Zhao","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Reyes, A., Muddasani, R., and Massarelli, E. (2024). Overcoming Resistance to Checkpoint Inhibitors with Combination Strategies in the Treatment of Non-Small Cell Lung Cancer. Cancers, 16.","DOI":"10.3390\/cancers16162919"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/14712598.2024.2408292","article-title":"The Frontier of Neoadjuvant Therapy in Non-Small Cell Lung Cancer beyond PD-(L)1 Agents","volume":"24","author":"Sposito","year":"2024","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in Resected ALK-Positive Non\u2013Small-Cell Lung Cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO-25-00883","article-title":"Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer","volume":"43","author":"He","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"101615","DOI":"10.1016\/j.xcrm.2024.101615","article-title":"Neoadjuvant Sintilimab plus Chemotherapy in EGFR-Mutant NSCLC: Phase 2 Trial Interim Results (NEOTIDE\/CTONG2104)","volume":"5","author":"Zhang","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"103994","DOI":"10.1016\/j.eclinm.2026.103994","article-title":"Neoadjuvant Sintilimab plus Chemotherapy in EGFR-Mutant Non-Small Cell Lung Cancer (NEOTIDE\/CTONG2104): Phase II Trial and Correlative Genomic Analysis in China","volume":"96","author":"Zhang","year":"2026","journal-title":"eClinicalMedicine"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"S1618","DOI":"10.1016\/j.annonc.2024.10.626","article-title":"599P Anlotinib Combined with Sintilimab versus Chemotherapy Combined with Immunotherapy in Perioperative NSCLC: A Phase II Study","volume":"35","author":"Chu","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"203","DOI":"10.21147\/j.issn.1000-9604.2021.02.08","article-title":"Clinical Challenges in Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer","volume":"33","author":"Guo","year":"2021","journal-title":"Chin. J. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Yu, A., Fu, F., Li, X., Wu, M., Yu, M., and Zhang, W. (2024). Perioperative Immunotherapy for Stage II-III Non-Small Cell Lung Cancer: A Meta-Analysis Base on Randomized Controlled Trials. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1351359"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/2933\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:19:32Z","timestamp":1789028372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/2933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":78,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18182933"],"URL":"https:\/\/doi.org\/10.3390\/cancers18182933","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]}}}